Literature DB >> 2426711

Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein.

J J Wang, S Steel, R Wisniewolski, C Y Wang.   

Abstract

A peptide of 21 amino acids with the sequence Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp- Gly-Cys - Ser encoded by a segment in the env gene of human T-lymphotropic virus type III (HTLV-III), corresponding to amino acids 586-606 of the precursor envelope glycoprotein, has been synthesized by the Merrifield solid-phase method. Combined serological and chemical analyses of this peptide and related peptides have revealed the importance of certain amino acid residues in the antigenic determinant of the relevant peptide. Enzyme immunoassay (EIA) employing this peptide as an antigen adsorbent was shown to reproducibly detect antibodies in sera of patients with HTLV-III infection. This assay provided positive results with all sera that were reactive with gp41 envelope protein of HTLV-III in electrophoretic immunoblot analysis. Thus far, no false-positive sera have been encountered in control populations. Our EIA with this peptide as the coating antigen is shown to have advantages over that with the whole HTLV-III virus as an immunoadsorbent.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426711      PMCID: PMC386459          DOI: 10.1073/pnas.83.16.6159

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

Authors:  R Sanchez-Pescador; M D Power; P J Barr; K S Steimer; M M Stempien; S L Brown-Shimer; W W Gee; A Renard; A Randolph; J A Levy
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

3.  Expression in Escherichia coli of open reading frame gene segments of HTLV-III.

Authors:  N T Chang; P K Chanda; A D Barone; S McKinney; D P Rhodes; S H Tam; C W Shearman; J Huang; T W Chang; R C Gallo
Journal:  Science       Date:  1985-04-05       Impact factor: 47.728

4.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

5.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

6.  Lymphadenopathy-associated viral antibody in AIDS. Immune correlations and definition of a carrier state.

Authors:  J Laurence; F Brun-Vezinet; S E Schutzer; C Rouzioux; D Klatzmann; F Barré-Sinoussi; J C Chermann; L Montagnier
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

7.  Association of HTLV-III antibodies and cellular immune status of hemophiliacs.

Authors:  C Tsoukas; F Gervais; J Shuster; P Gold; M O'Shaughnessy; M Robert-Guroff
Journal:  N Engl J Med       Date:  1984-12-06       Impact factor: 91.245

8.  Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain.

Authors:  R Cheingsong-Popov; R A Weiss; A Dalgleish; R S Tedder; D C Shanson; D J Jeffries; R B Ferns; E M Briggs; I V Weller; S Mitton
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

9.  Clinical findings and serological evidence of HTLV-III infection in homosexual contacts of patients with AIDS and persistent generalised lymphadenopathy in London.

Authors:  B G Gazzard; D C Shanson; C Farthing; A G Lawrence; R S Tedder; R Cheingsong-Popov; A Dalgleish; R A Weiss
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

10.  Aetiology of AIDS--antibodies to human T-cell leukaemia virus (type III) in haemophiliacs.

Authors:  L W Kitchen; F Barin; J L Sullivan; M F McLane; D B Brettler; P H Levine; M Essex
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

View more
  60 in total

1.  Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins.

Authors:  B Kobe; R J Center; B E Kemp; P Poumbourios
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

2.  Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.

Authors:  Christoph Grundner; Tajib Mirzabekov; Joseph Sodroski; Richard Wyatt
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  New sensitive and specific assay for human immunodeficiency virus antibodies using labeled recombinant fusion protein and time-resolved fluoroimmunoassay.

Authors:  H Siitari; P Turunen; J Schrimsher; M Nunn
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

4.  RNA-mediated transfer of cellular immunity to a synthetic env antigen of the human immunodeficiency virus (HIV-1).

Authors:  G A Passos Júnior; F L de Lucca
Journal:  Mol Cell Biochem       Date:  1991-11-13       Impact factor: 3.396

5.  Identification of a uniquely immunodominant, cross-reacting site in the human immunodeficiency virus endonuclease protein.

Authors:  E Björling; G Utter; P Stålhandske; E Norrby; F Chiodi
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

6.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

7.  Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.

Authors:  Henry E Neuman de Vegvar; Rama Rao Amara; Lawrence Steinman; Paul J Utz; Harriet L Robinson; William H Robinson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

Authors:  L E Brown; D O White; C Agius; B E Kemp; N Yatzakis; P Poumbourios; D A McPhee; D C Jackson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein.

Authors:  S S Chen; C N Lee; W R Lee; K McIntosh; T H Lee
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.